Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA OTCMKTS:JUSHF OTCMKTS:MDNAF NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.31+3.6%$1.32$0.87▼$2.99$94.42M-0.311.29 million shs362,306 shsJUSHFJushi$0.45-0.1%$0.48$0.35▼$0.98$89.77M-0.7161,781 shs71,204 shsMDNAFMedicenna Therapeutics$0.25-0.4%$0.32$0.25▼$1.43$23.09M1.7580,137 shs23,600 shsTHARTharimmune$2.34-2.1%$2.95$0.95▼$9.08$88.29M1.431.48 million shs784,773 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-2.33%-3.82%+8.62%-42.99%-34.03%JUSHFJushi-2.17%-1.10%-7.56%-11.76%+17.86%MDNAFMedicenna Therapeutics-1.88%-6.20%-13.29%-44.40%+25,119,900.00%THARTharimmune+3.91%+3.02%-25.55%-31.52%+46.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.31+3.6%$1.32$0.87▼$2.99$94.42M-0.311.29 million shs362,306 shsJUSHFJushi$0.45-0.1%$0.48$0.35▼$0.98$89.77M-0.7161,781 shs71,204 shsMDNAFMedicenna Therapeutics$0.25-0.4%$0.32$0.25▼$1.43$23.09M1.7580,137 shs23,600 shsTHARTharimmune$2.34-2.1%$2.95$0.95▼$9.08$88.29M1.431.48 million shs784,773 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-2.33%-3.82%+8.62%-42.99%-34.03%JUSHFJushi-2.17%-1.10%-7.56%-11.76%+17.86%MDNAFMedicenna Therapeutics-1.88%-6.20%-13.29%-44.40%+25,119,900.00%THARTharimmune+3.91%+3.02%-25.55%-31.52%+46.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 2.75Moderate Buy$8.50551.34% UpsideJUSHFJushi 3.00BuyN/AN/AMDNAFMedicenna Therapeutics 2.00HoldN/AN/ATHARTharimmune 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MDNAF, BMEA, JUSHF, and THAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/AJUSHFJushi$262.91M0.34N/AN/A($0.59) per share-0.76MDNAFMedicenna TherapeuticsN/AN/AN/AN/A$0.02 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)JUSHFJushi-$68.59M-$0.36N/AN/AN/A-26.90%N/A-16.59%8/4/2026 (Estimated)MDNAFMedicenna Therapeutics-$13.32M-$0.16N/AN/AN/AN/A-1.37%-0.65%N/ATHARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/ALatest MDNAF, BMEA, JUSHF, and THAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026BMEABiomea Fusion-$0.21N/AN/AN/AN/AN/A8/4/2026N/AJUSHFJushi-$0.06N/AN/AN/A$67.47 millionN/A6/25/2026Q4 2026MDNAFMedicenna Therapeutics-$0.05-$0.05N/A-$0.06N/AN/A5/12/2026Q1 2026JUSHFJushi-$0.06-$0.10-$0.04-$0.10$67.05 million$66.43 million5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AJUSHFJushiN/AN/AN/AN/AN/AMDNAFMedicenna TherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A4.984.98JUSHFJushiN/A1.130.65MDNAFMedicenna TherapeuticsN/A1.521.52THARTharimmuneN/A4.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%JUSHFJushi21.68%MDNAFMedicenna Therapeutics35.85%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion10.60%JUSHFJushi23.13%MDNAFMedicenna Therapeutics33.10%THARTharimmune6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5072.30 million64.64 millionOptionableJUSHFJushi1,288199.70 million153.51 millionNot OptionableMDNAFMedicenna Therapeutics2092.30 million61.75 millionN/ATHARTharimmune237.73 million35.20 millionNot OptionableMDNAF, BMEA, JUSHF, and THAR HeadlinesRecent News About These CompaniesTharimmune Stockholders Elect Board, Ratify Auditor at 2026 Annual MeetingJuly 13, 2026 | marketbeat.comTharimmune (NASDAQ:THAR) Shares Down 7.2% - Time to Sell?July 10, 2026 | americanbankingnews.comTharimmune Inc.May 13, 2026 | wsj.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comIs Canton’s price set to explode amid Tharimmune’s rebrand?February 17, 2026 | invezz.comITharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comTharimmune Approved as Super Validator on Canton NetworkJanuary 27, 2026 | theglobeandmail.comTharimmune Announces Expanded Role as Super Validator on Canton NetworkJanuary 26, 2026 | prnewswire.comTharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On TokenizationJanuary 23, 2026 | seekingalpha.comTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct OfferingJanuary 22, 2026 | prnewswire.comTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered OfferingJanuary 20, 2026 | prnewswire.comTharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton NetworkDecember 18, 2025 | prnewswire.comTharimmune appoints Jacob Asbury as CFODecember 12, 2025 | msn.comTharimmune Appoints Jacob Asbury as New CFODecember 12, 2025 | tipranks.comTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury StrategyDecember 12, 2025 | businesswire.comTharimmune files to sell 176.93M shares of common stock for holdersDecember 5, 2025 | msn.comCrypto Company Creates Bizarre DrugNovember 22, 2025 | msn.comTharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?November 22, 2025 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDNAF, BMEA, JUSHF, and THAR Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.30 +0.05 (+3.57%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Jushi OTCMKTS:JUSHF$0.45 0.00 (-0.11%) As of 12:40 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.Medicenna Therapeutics OTCMKTS:MDNAF$0.25 0.00 (-0.40%) As of 01:32 PM EasternMedicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.Tharimmune NASDAQ:THAR$2.34 -0.05 (-2.09%) As of 07/16/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout J.B. Hunt Stock Could Reach $340 as Trucking Capacity Shrinks The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
